Skip to main content

Advertisement

SpringerLink
Log in

Effects of Testosterone on Benign and Malignant Conditions of the Prostate

  • Male Sexual Dysfunction and Disorders (AW Pastuszak and TS Köhler, Section Editors)
  • Published:
Current Sexual Health Reports Aims and scope Submit manuscript

Abstract

Purpose of the Review

This review summarizes the current literature regarding the effects of testosterone therapy (TTh) on common disorders of the prostate.

Recent Findings

Testosterone therapy has gained credibility over the last several decades as a potentially safe co-treatment modality for men with benign and malignant prostatic conditions. Our understanding of the effects of testosterone on the prostate continues to evolve with on-going clinical and basic science research. Findings of these studies have reinvigorated the debate over the effects of testosterone on benign and malignant disorders of the prostate, including BPH, chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), and prostate cancer.

Summary

Despite the burgeoning body of data claiming the safety and efficacy of TTh in common prostatic conditions (including BPH, CP/CPPS, and prostate cancer), diligent monitoring, appropriate patient selection, and informed consent are critical until more definitive studies are performed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Handelsman DJ. Global trends in testosterone prescribing, 2000–2011: expanding the spectrum of prescription drug misuse. Med J Aust. 2013;199(8):548–51.

    Article  PubMed  Google Scholar 

  2. Desroches B, Kohn TP, Welliver C, Pastuszak AW. Testosterone therapy in the new era of Food and Drug Administration oversight. Transl Androl Urol. 2016;5(2):207–12.

    Article  PubMed  PubMed Central  Google Scholar 

  3. •• Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972;22(4):232–40. This historical study reported regression of prostate cancer with testosterone reduction and conversly that administration of testosterone caused prostate cancer to grow

    Article  CAS  PubMed  Google Scholar 

  4. Prout Jr GR, Brewer WR. Response of men with advanced prostatic carcinoma to exogenous administration of testosterone. Cancer. 1967;20(11):1871–8.

    Article  PubMed  Google Scholar 

  5. Fowler Jr JE, Whitmore Jr WF. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol. 1981;126(3):372–5.

    PubMed  Google Scholar 

  6. Ho SM, Damassa D, Kwan PW, Seto HS, Leav I. Androgen receptor levels and androgen contents in the prostate lobes of intact and testosterone-treated Noble rats. J Androl. 1985;6(5):279–90.

    Article  CAS  PubMed  Google Scholar 

  7. Rhodes T, Girman CJ, Jacobsen SJ, Roberts RO, Guess HA, Lieber MM. Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol. 1999;161(4):1174–9.

    Article  CAS  PubMed  Google Scholar 

  8. Holmang S, Marin P, Lindstedt G, Hedelin H. Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men. Prostate. 1993;23(2):99–106.

    Article  CAS  PubMed  Google Scholar 

  9. Bhasin S, Parker RA, Sattler F, Haubrich R, Alston B, Umbleja T, et al. Effects of testosterone supplementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesity. J Clin Endocrinol Metab. 2007;92(3):1049–57.

    Article  CAS  PubMed  Google Scholar 

  10. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur Urol. 2009;55(1):121–30.

    Article  PubMed  Google Scholar 

  11. Sih R, Morley JE, Kaiser FE, Perry HM, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab. 1997;82(6):1661–7.

    Article  CAS  PubMed  Google Scholar 

  12. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci. 2001;56(5):M266–72.

    Article  CAS  PubMed  Google Scholar 

  13. Kenny AM, Kleppinger A, Annis K, Rathier M, Browner B, Judge JO, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc. 2010;58(6):1134–43.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006;296(19):2351–61.

    Article  CAS  PubMed  Google Scholar 

  15. Paduch DA, Polzer PK, Ni X, Basaria S. Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. J Clin Endocrinol Metab. 2015:jc20144434.

  16. Meuleman EJ, Legros JJ, Bouloux PM, Johnson-Levonas AO, Kaspers MJ, Elbers JM, et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. The aging male : the official journal of the International Society for the Study of the Aging Male. 2015:1–7.

  17. Konaka H, Sugimoto K, Orikasa H, Iwamoto T, Takamura T, Takeda Y, et al. Effects of long-term androgen replacement therapy on the physical and mental statuses of aging males with late-onset hypogonadism: a multicenter randomized controlled trial in Japan (EARTH Study). Asian journal of andrology. 2015;

  18. Cui Y, Zhang Y. The effect of androgen-replacement therapy on prostate growth: a systematic review and meta-analysis. Eur Urol. 2013;64(5):811–22.

    Article  CAS  PubMed  Google Scholar 

  19. Kohn TP, Mata DA, Ramasamy R, Lipshultz LI. Effects of testosterone replacement therapy on lower urinary tract symptoms: a systematic review and meta-analysis. Eur Urol. 2016;

  20. Pechersky AV, Mazurov VI, Semiglazov VF, Karpischenko AI, Mikhailichenko VV, Udintsev AV. Androgen administration in middle-aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume. Int J Androl. 2002;25(2):119–25.

    Article  CAS  PubMed  Google Scholar 

  21. Shigehara K, Sugimoto K, Konaka H, Iijima M, Fukushima M, Maeda Y, et al. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. The Aging Male: The Official Journal of the International Society for the Study of the Aging Male. 2011;14(1):53–8.

    Article  Google Scholar 

  22. Meikle AW, Stephenson RA, Lewis CM, Middleton RG. Effects of age and sex hormones on transition and peripheral zone volumes of prostate and benign prostatic hyperplasia in twins. J Clin Endocrinol Metab. 1997;82(2):571–5.

    CAS  PubMed  Google Scholar 

  23. DeLay KJ, Kohler TS. Testosterone and the prostate: artifacts and truths. Urol Clin North Am. 2016;43(3):405–12.

    Article  PubMed  Google Scholar 

  24. Herati AS, Moldwin RM. Prostatitis, chronic nonbacterial, inflammatory and Noninflammatory (NIH CP/CPPS IIIA AND IIIB). In: Gomella LG, editor. 5-minute urology consult. 1. 3RD ed. Philadelphia: Wolters Kluwer; 2015. p. 356–7.

    Google Scholar 

  25. McNaughton Collins M, Pontari MA, O'Leary MP, Calhoun EA, Santanna J, Landis JR, et al. Quality of life is impaired in men with chronic prostatitis: the Chronic Prostatitis Collaborative Research Network. J Gen Intern Med. 2001;16(10):656–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Pontari MA, Ruggieri MR. Mechanisms in prostatitis/chronic pelvic pain syndrome. J Urol. 2008;179(5 Suppl):S61–7.

    Article  PubMed  Google Scholar 

  27. Mehik A, Hellstrom P, Nickel JC, Kilponen A, Leskinen M, Sarpola A, et al. The chronic prostatitis-chronic pelvic pain syndrome can be characterized by prostatic tissue pressure measurements. J Urol. 2002;167(1):137–40.

    Article  PubMed  Google Scholar 

  28. Rees RW, Foxwell NA, Ralph DJ, Kell PD, Moncada S, Cellek S. Y-27632, a Rho-kinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells. J Urol. 2003;170(6 Pt 1):2517–22.

    Article  CAS  PubMed  Google Scholar 

  29. Hayek OR, Shabsigh A, Kaplan SA, Kiss AJ, Chen MW, Burchardt T, et al. Castration induces acute vasoconstriction of blood vessels in the rat prostate concomitant with a reduction of prostatic nitric oxide synthase activity. J Urol. 1999;162(4):1527–31.

    Article  CAS  PubMed  Google Scholar 

  30. Tsilidis KK, Rohrmann S, McGlynn KA, Nyante SJ, Lopez DS, Bradwin G, et al. Association between endogenous sex steroid hormones and inflammatory biomarkers in US men. Andrology. 2013;1(6):919–28.

    Article  CAS  PubMed  Google Scholar 

  31. Byun JS, Yoon TK, Rhee HW, Kim JH, Shin JS, Kim HS, et al. Chronic pelvic pain syndrome and semen quality of Korean men in their fourth decade. J Androl. 2012;33(5):876–85.

    Article  CAS  PubMed  Google Scholar 

  32. Lee JH, Lee SW. Testosterone and chronic prostatitis/chronic pelvic pain syndrome: a propensity score-matched analysis. J Sex Med. 2016;13(7):1047–55.

    Article  PubMed  Google Scholar 

  33. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.

    Article  PubMed  Google Scholar 

  34. Golabek T, Belsey J, Drewa T, Kolodziej A, Skoneczna I, Milecki P, et al. Evidence-based recommendations on androgen deprivation therapy for localized and advanced prostate cancer. Cent European J Urol. 2016;69(2):131–8.

    PubMed  PubMed Central  Google Scholar 

  35. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215–24.

    Article  CAS  PubMed  Google Scholar 

  36. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362(13):1192–202.

    Article  CAS  PubMed  Google Scholar 

  37. Thirumalai A, Cooper LA, Rubinow KB, Amory JK, Lin DW, Wright JL, et al. Stable Intraprostatic dihydrotestosterone in healthy medically castrate men treated with exogenous testosterone. J Clin Endocrinol Metab. 2016;101(7):2937–44.

    Article  CAS  PubMed  Google Scholar 

  38. Rizner TL, Lin HK, Peehl DM, Steckelbroeck S, Bauman DR, Penning TM. Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells. Endocrinology. 2003;144(7):2922–32.

    Article  CAS  PubMed  Google Scholar 

  39. Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology. 2006;68(6):1263–7.

    Article  PubMed  Google Scholar 

  40. Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Urol. 2000;163(3):824–7.

    Article  CAS  PubMed  Google Scholar 

  41. Garcia-Cruz E, Piqueras M, Ribal MJ, Huguet J, Serapiao R, Peri L, et al. Low testosterone level predicts prostate cancer in re-biopsy in patients with high grade prostatic intraepithelial neoplasia. BJU Int. 2012;110(6 Pt B):E199–202.

    Article  CAS  PubMed  Google Scholar 

  42. Garcia-Cruz E, Piqueras M, Huguet J, Peri L, Izquierdo L, Musquera M, et al. Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment. BJU Int. 2012;110(11 Pt B):E541–6.

    Article  CAS  PubMed  Google Scholar 

  43. Teloken C, Da Ros CT, Caraver F, Weber FA, Cavalheiro AP, Graziottin TM. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J Urol. 2005;174(6):2178–80.

    Article  CAS  PubMed  Google Scholar 

  44. Salonia A, Gallina A, Briganti A, Abdollah F, Suardi N, Capitanio U, et al. Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy. Cancer. 2011;117(17):3953–62.

    Article  PubMed  Google Scholar 

  45. Lane BR, Stephenson AJ, Magi-Galluzzi C, Lakin MM, Klein EA. Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy. Urology. 2008;72(6):1240–5.

    Article  PubMed  Google Scholar 

  46. Yamamoto S, Yonese J, Kawakami S, Ohkubo Y, Tatokoro M, Komai Y, et al. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol. 2007;52(3):696–701.

    Article  CAS  PubMed  Google Scholar 

  47. Morgentaler A. Two years of testosterone therapy associated with decline in prostate-specific antigen in a man with untreated prostate cancer. J Sex Med. 2009;6(2):574–7.

    Article  PubMed  Google Scholar 

  48. Morgentaler A, Lipshultz LI, Bennett R, Sweeney M, Avila Jr D, Khera M. Testosterone therapy in men with untreated prostate cancer. J Urol. 2011;185(4):1256–60.

    Article  CAS  PubMed  Google Scholar 

  49. Morales A. Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry. BJU Int. 2011;107(9):1369–73.

    Article  PubMed  Google Scholar 

  50. San Francisco IF, Werner L, Regan MM, Garnick MB, Bubley G, DeWolf WC. Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance. J Urol. 2011;185(2):471–6.

    Article  PubMed  Google Scholar 

  51. Kacker R, Hult M, San Francisco IF, Conners WP, Rojas PA, Dewolf WC, et al. Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results. Asian journal of andrology. 2016;18(1):16–20.

    Article  CAS  PubMed  Google Scholar 

  52. Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2004;172(3):920–2.

    Article  CAS  PubMed  Google Scholar 

  53. Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol. 2005;173(2):533–6.

    Article  CAS  PubMed  Google Scholar 

  54. Pastuszak AW, Pearlman AM, Lai WS, Godoy G, Sathyamoorthy K, Liu JS, et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol. 2013;190(2):639–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007;109(3):536–41.

    Article  CAS  PubMed  Google Scholar 

  56. Balbontin FG, Moreno SA, Bley E, Chacon R, Silva A, Morgentaler A. Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer. BJU Int. 2014;114(1):125–30.

    Article  CAS  PubMed  Google Scholar 

  57. Pastuszak AW, Pearlman AM, Godoy G, Miles BJ, Lipshultz LI, Khera M. Testosterone replacement therapy in the setting of prostate cancer treated with radiation. Int J Impot Res. 2013;25(1):24–8.

    Article  CAS  PubMed  Google Scholar 

  58. Wadosky KM, Koochekpour S. Therapeutic rationales, progresses, failures, and future directions for advanced prostate cancer. Int J Biol Sci. 2016;12(4):409–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Kokontis JM, Hay N, Liao S. Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol. 1998;12(7):941–53.

    Article  CAS  PubMed  Google Scholar 

  60. Umekita Y, Hiipakka RA, Kokontis JM, Liao S. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci U S A. 1996;93(21):11802–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Song W, Khera M. Physiological normal levels of androgen inhibit proliferation of prostate cancer cells in vitro. Asian J Androl. 2014;16(6):864–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Lin C, Yang L, Tanasa B, Hutt K, Ju BG, Ohgi K, et al. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell. 2009;139(6):1069–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet. 2010;42(8):668–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Morris MJ, Huang D, Kelly WK, Slovin SF, Stephenson RD, Eicher C, et al. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Eur Urol. 2009;56(2):237–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Szmulewitz R, Mohile S, Posadas E, Kunnavakkam R, Karrison T, Manchen E, et al. A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol. 2009;56(1):97–103.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. • Schweizer MT, Antonarakis ES, Wang H, Ajiboye AS, Spitz A, Cao H, et al. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Sci Transl Med. 2015;7(269):269ra2. This study demonstrated pilot data for a novel therapeutic approach to the treatment of asymptomatic castration-resistant prostate cancer by targeting the androgren receptor overexpression

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Reproductive Medicine, Baylor College of Medicine, 6624 Fanin Street, Houston, TX, 77030, USA

    Amin S. Herati, Peter R. Butler & Larry I. Lipshultz

  2. Scott Department of Urology, Baylor College of Medicine, 6624 Fanin Street, Houston, TX, 77030, USA

    Amin S. Herati, Taylor P. Kohn, Peter R. Butler & Larry I. Lipshultz

Authors
  1. Amin S. Herati
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Taylor P. Kohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter R. Butler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Larry I. Lipshultz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Larry I. Lipshultz.

Ethics declarations

Conflict of Interest

Amin S. Herati, Taylor P. Kohn, Peter R. Butler, and Larry I. Lipshultz each declare no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Funding

A.S.H. is a National Institutes of Health (NIH) K12 Scholar supported by a Male Reproductive Health Research (MHRH) Career Development Physician-Scientist Award (HD073917-01) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Program (to Dolores J. Lamb).

Additional information

This article is part of the Topical Collection on Male Sexual Dysfunction and Disorders

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Herati, A.S., Kohn, T.P., Butler, P.R. et al. Effects of Testosterone on Benign and Malignant Conditions of the Prostate. Curr Sex Health Rep 9, 65–73 (2017). https://doi.org/10.1007/s11930-017-0104-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11930-017-0104-7

Keywords

Search

Navigation